Abstract 2047
Background
TSAs are common side effects among cancer pts undergoing chemotherapy and may lead to inadequate dietary intake and reduced quality of life. Here, we investigate the incidence of multiple components of self-reported TSAs and its etiological determinants in a homogeneous group of pts with stage II-III CC.
Methods
We used data collected in an ongoing observational study within the Prospective Dutch Colorectal Cancer Cohort, designed to study nutritional factors and oncological outcomes. Pts receive questionnaires on dietary intake by food-frequency questionnaire (past month average intake), dietary supplement use and TSAs at diagnosis (T0), and at 6, 12, 24 months post-diagnosis. Here, we selected pts with stage II-III CC, with completed T6 questionnaires and available clinical data.
Results
We included 87/468 pts for analysis (updated for ESMO) with a mean age 64.0±7.6 years, 70% male and 70% current/former smokers. Adjuvant chemotherapy (ACT), received by 52% of pts, consisted of CAPOX (90%), FOLFOX (5%), or CAP (5%) as initial regimen. TSAs were reported at T0 (4% of pts) and at T6 (32% of pts). TSA presence was significantly related to receiving ACT (RR 13.8, 95%CI: 3.5-54.3), but not to age, sex, education and smoking status. ACT treated pts more often reported a change in taste ability (49%, p < 0.001), change in taste perception (51%, p < 0.001), dry mouth (29%, p < 0.001), bad taste (38%, p < 0.001), and metallic taste (18%, p = 0.006), compared to pts who did not receive ACT. Pts with TSAs did not significantly differ from pts without TSAs in terms of caloric intake at T6 (p = 0.69). Caloric intake was low (no-TSA (n = 59) 1772 kCal and TSA (n = 28) 1809 kCal) and was below the ESPEN guidelines on nutrition in cancer patients for both groups.
Conclusions
TSAs are more prevalent in CC pts who received ACT compared to pts who did not, with taste more affected than smell. Pts had caloric intake below guideline recommendations at T6. The influence of TSAs on caloric intake appears to be limited when caloric intake is already insufficient. More pts, follow-up, and data on macronutrients and quality of life are needed to confirm and enrich these preliminary findings and ultimately help improve supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Province of Utrecht, The Netherlands.
Disclosure
B. Dorresteijn: Full / Part-time employment: Danone Nutricia Research. M. Jourdan: Full / Part-time employment: Danone Nutricia Research. All other authors have declared no conflicts of interest.
Resources from the same session
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract